(Total Views: 500)
Posted On: 08/17/2019 8:12:29 AM
Post# of 154852
A game, after ISW post, thinking again about combo sales. I thought of this when I woke, saw others posting as well this morning. So maybe relevant to everyone thinking.
Just combo enrollment in 2020, not off-label mono or off-label cancer if early ctc numbers come back great. Assuming approval early 2019. Once the BLA is submitted I'm at 99% approval, though not reviews are first pass. Also I predict around 3-6months as with most hiv drug approvals after bla.
Anyway combo enrollment 2020? What price with leronlimab be at?
Remember the MDR2+ group is 200k, but not all are R5.
Just combo enrollment in 2020, not off-label mono or off-label cancer if early ctc numbers come back great. Assuming approval early 2019. Once the BLA is submitted I'm at 99% approval, though not reviews are first pass. Also I predict around 3-6months as with most hiv drug approvals after bla.
Anyway combo enrollment 2020? What price with leronlimab be at?
Remember the MDR2+ group is 200k, but not all are R5.
(0)
(0)
